There was no difference in the primary end-point , median progression-free survival ( PFS ) for gemcitabine plus sorafenib versus gemcitabine plus placebo ( @ versus @ months , P = @ ) , and no difference for median overall survival ( OS ) ( @ versus @ months , P = @ ) .